Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1LP4B
|
|||
| Drug Name |
PF-07264660
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Atopic dermatitis [ICD-11: EA80; ICD-10: L20] | Phase 1 | [1] | |
| Company |
Pfzer
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05496738) A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE AND MULTIPLE INTRAVENOUS AND SUBCUTANEOUS DOSES OF PF-07264660 IN HEALTHY PARTICIPANTS. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Pfizer | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.